Oncotarget journal contribution to informative research

Oncotarget is a peer reviewed open access medical journal published weekly. It covers all oncology research related articles. The journal was founded in 2010 and is printed by Impact Journal. Mikhail Blagosklonny and Andrei V. Gudkov are the editors-in-chief. The journal is applauded for being creative, constructive, insightful, and punctual. It has multiple peer reviews. The peer review has enabled Oncotarget authors to do a very influential research. The Oncotarget accepts papers on topics such as Endocrinology, Pharmacology, Neuroscience, Cardiology, Cell Biology and Metabolism which are beyond Oncology. It is considered as one of the best multidisciplinary journals with free access to researchers. Oncotarget provides online papers in weekly issues. The public can print issue or paper at a special demand.

The mission of this renowned journal is to make scientific results easily and widely accessible. They intend to leverage on the impact of the research through thorough and insightful peer reviews. The journal allows superb discoveries to be shared widely and faster. The journal has helped to eliminate the barrier between specialties and to connect various fields of biomedical sciences. It supports applications of basic and clinical science to fight disease. Through the leadership of the most eminent scientists, the Oncotarget journal assists researchers to contribute towards the progress and development of science. They are aiming for a life free from disease.

Mikhail Blagosklonny is a former professor of oncology at the Roswell Park Cancer Institute in New York. He is a scientist and focuses his study on cancer and aging. He attended First Pavlov State Medical University of St. Peterburg where he earned his M.D. in internal medicine and Ph.D. in experimental medicine and cardiology. In 2002, he was appointed as an associate professor of medicine at New York medical college, Valhalla, NY. He then became a senior scientist at Ordway Research Institute, Albany, New York. In 2009, he became a professor of oncology at Roswell Park Cancer Institute. He is interested in researching cancer therapies that protect normal cells from damage and mechanisms beneath aging and anti-aging drugs. He is editor-in-chief of Oncotarget, Aging and Cell Cycle.

Copa Star: Revolutionizing the Medical Industry

Technology has taken the world by storm and changed life as we know it. However, the perfect use of technology has been seen in the new luxurious hospital in Rio de Janeiro- Copa Star. The unification of artwork, technology, and architecture has come alive in this hospital. The architectural design of the hospital resembles a five-star hotel.

At the reception, you will be welcomed by the beautiful artwork of the Japanese artist Yutaka Toyota. They have included other distractions like a grand piano and art books.

An investment of $R400 million has gone towards designing the hospital. The primary goal of the hospital is to be the best in cardiology and neurology and also surpass the leading hospitals in Rio de Janeiro like Albert Einstein Hospital. View the design at RafArquitetura.Com

Rede D’Or hopes to open other similar hospitals across the State of Brazil.

The architecture

Did you know it took three years for the hospital to be completed? That is the reason why it beams with elegance and class. The Rede D’Or network owns the hospital, and they have applied the same architectural design seen in all their hospitals. The hospital seats on a 21,000 Square Meters and has different rooms including I.C.U, Operating rooms, and patients suites.

Copa Star has a glass ceiling that displays natural light in the hospital’s hallway. It also helps to provide warmth in the hospital.

They have a modern restaurant attached to the hospital. The hospital offers different cuisines that you will enjoy.


The hospital is making use of the robotic medicine in the operating rooms. It is a new concept in the medical world. The neurosurgery rooms have been equipped with magnetic resonance imaging equipment.

The patients’ suites have been fitted with iPads with an app designed specifically for the hospital use. With these iPads, the patients can control the essential functions of the hospital like opening and closing of the curtains and adjust the lighting in the rooms. They can also use the devices to communicate with the doctors. The doctors, on the other hand, use the iPads to display the patient’s radiology results.

The hospital’s Intensive Care Units have a state-of-the-art design. While at the hospital, the patients will not get lonely as there are large screens fitted in the rooms. These screens display real-time images transmitted from the Cameras installed outside. The agenda of the hospital is to reduce the boredom and loneliness that the patients experience.


It is their quality service that makes all the difference. The hospital has a team of qualified nurses and doctors who are dedicated to offering you with the best patient care. The nurses undergo a two-month training that equips them with all the skills of handling different patients.

The Number One Peer-Review Medical Journal Portal Oncotarget

Oncology is a remarkably broad and traverse niche with new developments getting released constantly. You can imagine the frustrations faced by independent cancer researchers as they attempt to come up with new innovations and treatment. It feels as if they are operating blind without knowing whether another scientist on a remote part of the world has already worked on that particular problem set or approach. Such handicaps often lead to delayed progress in the elusive search for viable cancer cure therapies; much to the detriment of the millions of cancer patients, globally. Oncotarget is a privately owned online medical journal whose primary goal is to pool together all the relevant medical findings on oncology in one place.

Oncortarget’s Chief Editors

This movement started in 2010 and the driving forces behind the idea came from two of the most prolific cancer scientists in the nation. The main roles played by the co-founders, Mikhail Blagosklonny and Andrei V. Gudkov, at Oncortarget mostly involve proof-reading, testing and analysis of the submitted medical abstract journals before they finally publish them to the world. Today, Oncotarget has posted a large number of fascinating content talking about patient’s experiences upon using some of the latest cancer therapies and treatments hitting the marketplace.

Follow: https://twitter.com/oncotargetjrnl?lang=en

Open Access Policy

Oncotarget is an influential peer-reviewed oncology journal which lets researchers and scholars quickly share their study findings with the rest of the world. One of the golden rules is that the contributors must consent to the distribution of their work online. For the past five years, the establishment has scored an average Journal Impact Factor of 2.235, according to Dovepress.com


On the other hand, the Thomson Reuters JCR Impact Factor has placed Oncortaget first out of all the peer review journals available, for the last six years, back to back. Reuters Factor repeatedly stated the efficient and systematic methodology used by the staff at Oncotarget to filter journals as one of the top reasons they topped their prestigious rating. The unprecedented success of the establishment has seen it expand its portfolio to now accept medical journals from other field’s asides oncology. The new medical genres, authors can now publish on include pharmacology, microbiology, neurosciences and in cardiology. Visit his profile on Google Scholar.

Dr. Shiva Gopal Vasishta and His Contribution towards Fighting Multiple Sclerosis

Among the many treatments for Multiple Sclerosis (MS) in the medical industry, most of them are short-term solution to the disorder. Recently, there has been a new clinical trial which has shown results that can provide long-term treatment for MS. In this trial, participants with multiple sclerosis were provided with five years of treatment using high-dose immunosuppressive therapy along with hematopoietic cell transplant. The results of the trial showed that 69 percent of people survived the test and did not experience relapse or any other brain lesion. The participants did not take any other medication during the trial. The participants for the trial had volunteered with MS in the age ranging from 26 to 52 years and were experiencing worsening of their condition.


The trial known as HALT-MS was sponsored by the National Institute of Allergy and Infectious Diseases and was carried out by Immune Tolerance Network funded by NIAID. While the results of the three years study in 2014 showed promising future for such treatment, the new findings prove that the new one-time treatment is more effective for people suffering from MS. The next step is to compare the treatment with other MS treatments to show its effectiveness on a much larger scale.


One of the most famous neurologists working in this field is Dr. Shiva Gopal Vasishta. He is currently associated with the Kennedy University Hospital. Dr Shiva Gopal Vasishta earned his degree from the Government Medical College in India in medicine and psychiatry in 1979 where he passed the top of the class. He then went on to complete his residency at Boston City Hospital.


Dr Shiva Gopal Vasishta also practices at the Eastern Neurodiagnostic Associates where he is part of the team that treats patients with advanced brain disorders. Dr Shiva Gopal Vasishta even treats those who are unable to pay for their treatment which shows the passion and commitment he has for his profession.